Yeomans Consulting Group Inc. Sells 515 Shares of Verona Pharma PLC American Depositary Share $VRNA

Yeomans Consulting Group Inc. trimmed its position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 13.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,287 shares of the company’s stock after selling 515 shares during the period. Yeomans Consulting Group Inc.’s holdings in Verona Pharma PLC American Depositary Share were worth $297,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in VRNA. Frazier Life Sciences Management L.P. increased its holdings in shares of Verona Pharma PLC American Depositary Share by 2.2% in the first quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company’s stock worth $219,539,000 after purchasing an additional 73,900 shares during the period. Price T Rowe Associates Inc. MD grew its position in Verona Pharma PLC American Depositary Share by 1.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company’s stock worth $118,491,000 after buying an additional 32,748 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Verona Pharma PLC American Depositary Share by 381.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company’s stock worth $103,552,000 after acquiring an additional 1,292,575 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Verona Pharma PLC American Depositary Share by 274.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock valued at $66,119,000 after acquiring an additional 763,353 shares in the last quarter. Finally, Duquesne Family Office LLC raised its holdings in shares of Verona Pharma PLC American Depositary Share by 12.9% in the 1st quarter. Duquesne Family Office LLC now owns 1,002,080 shares of the company’s stock valued at $63,622,000 after acquiring an additional 114,500 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Verona Pharma PLC American Depositary Share Price Performance

Shares of VRNA opened at $106.82 on Friday. The firm has a market cap of $9.21 billion, a P/E ratio of -107.90 and a beta of 0.05. The stock has a 50 day simple moving average of $105.88 and a two-hundred day simple moving average of $87.39. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. Verona Pharma PLC American Depositary Share has a 1 year low of $29.25 and a 1 year high of $106.86.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The firm had revenue of $103.14 million for the quarter, compared to the consensus estimate of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. On average, analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Kathleen A. Rickard sold 58,336 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $766,535.04. Following the transaction, the insider directly owned 2,607,472 shares of the company’s stock, valued at approximately $34,262,182.08. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Martin Edwards sold 10,808 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $142,017.12. Following the completion of the transaction, the director owned 157,992 shares in the company, valued at approximately $2,076,014.88. This represents a 6.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 540,584 shares of company stock worth $7,103,274 over the last 90 days. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on VRNA shares. Cowen lowered Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. BTIG Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Wolfe Research cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Wells Fargo & Company lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and decreased their price target for the stock from $138.00 to $107.00 in a report on Thursday, July 10th. Finally, Piper Sandler downgraded shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Two analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.